Genzyme Acquisitions and Exits, 15 Deals Between 1992 and 2015
life science Company

Genzyme has acquired 16 companies of its own, including 1 in the last 5 years. A total of 8 acquisitions came from private equity firms. It has also divested 3 assets.

Genzyme’s largest acquisition to date was in 2004, when it acquired ILEX Oncology for $1.0B. It’s largest disclosed sale occurred in 2010, when it sold Genzyme Genetics to Laboratory of America Holdings for $925M. Genzyme has acquired in 8 different US states, and 4 countries. The Company’s most targeted sectors include life science (75%) and medical products (25%).

Join Mergr and gain access to Genzyme’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

Genzyme Corp.

500 Kendall Street,
Cambridge, Massachusetts 02142
United States,
(617) 252-7500
www.genzyme.com

Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.

M&A Summary

Buy vs Sell

Year ≤ '14 '15 '16 '17 '18 '19 T
Buy (0.2/yr) # 11 1 - - - - 12
vol $4.4B $4.4B
Sell (0.0/yr) # 3 - - - - - 3
vol $1.2B $1.2B
  15

Top M&A Advisors

Financial Deals
Sign-up to View
1
Sign-up to View
1
Legal Deals
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest ILEX Oncology, Inc.
$1.0B (2004-12-21)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Genzyme Genetics
$925M (2010-12-01)

Life Science M&A - Last 3 Years

Genzyme was acquired by Sanofi SA on February 16, 2011.

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 391 life science companies that have made at least 1 acquisition, 12 have acquired at least 5 companies, and 3 have acquired more than 10 companies.

The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 22 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Avista Capital Partners with 6 platform acquisitions.


What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.6K Private Equity Firms
  • 128K M&A Transactions
  • 137K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.9K M&A Advisors
    (Investment Banks and Law Firms)
  • 36K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.